The pex gene: Its role in X-linked rickets, osteomalacia, and bone mineral metabolism

Experimental Nephrology

Volumn 5, Issue 5, 1997, Pages 355-363

  Rowe, Peter S N ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bone; Kidney; Oncogenic osteomalacia; PEX gene; Phosphate vitamin D metabolism; Stanniocalcin; X linked hypophosphataemic rickets; Zinc metallopeptidases

Indexed keywords

ANIMAL CELL; BONE METABOLISM; BONE MINERAL; GENE ISOLATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; OSTEOMALACIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATOR GENE; RICKETS; SHORT SURVEY; VITAMIN D RESISTANT RICKETS;

BONE DENSITY; CLONING, MOLECULAR; HUMANS; HYPOPHOSPHATEMIA, FAMILIAL; MUTATION; OSTEOMALACIA; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEINS;

EID: 0030661692     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (75)

1. McKusick VA, Francomano CA, Antonarakis SE: Mendelian Inheritance in Man: Catalogs of Autosomal Dominant, Autosomal Recessive and X-Linked Phenotypes, ed 10, Baltimore, Johns Hopkins University Press, 1992.
2. Rowe PSN: Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 1994;94:457-467.
3. Drezner MK: Tumour associated rickets and osteomalacia; in Favus MJ (ed): Primer on Metablic Bone Diseases and Disorders of Mineral Metabolism. Kelseyville, American Society for Bone Mineral Research, 1990, pp 184-188.
4. Drezner MK: Understanding the pathogenesis of X-linked hypophosphataemic rickets: A requisite for successful therapy; in A CPC Series: Cases in Metabolic Bone Disease. New York, Triclinica Communications, vol 2, pp 1-11.
5. Alon U, Chan JCM: Effects of hydrochlorothiazide and amiloride in renal hypophosphataemic rickets. Pediatrics 1985;75:754-763.
6. Stickler GB, Morgenstern BZ: Hypophosphataemic rickets: Final height and clinical symptoms in adults. Lancet 1989;ii:902-905.
7. Alon U, Newsome H, Cham JCM: Hyperparathyroidism in patients with X-linked dominant hypophosphataemic rickets: Application of the calcium infusion test as an an indicator of parathyroidectomy. Int J Paediatr Nephrol 1984;5: 39.
8. Reusz GS, Latta K, Hoyer PF, Byrd DJ, Ehrich JHH, Brodehl J: Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets. Lancet 1990;335:1240-1243.
9. Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver MD: Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Paediatr 1987;111:701-704.
10. Winters RW, Graham JB, Williams TF, McFalls VW, Burnett CH: A genetic study of familial hypophosphataemia and vitamin D resistant rickets with a review of the literature. Medicine (Baltimore) 1958;37:97-142.
11. Albright F, Butler AM, Bloomberg E: Rickets resistant to vitamin D therapy. Am J Dis Child 1937;54:529-547.
12. Rowe PSN, Goulding JN, Francis F, Oudet C, Econs M, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J, Fraser W, Drezner MK, Davies KE, O'Riordan JLH: The gene for X-linked hypophosphataemic rickets maps to a 200-300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet 1996;97:345-352.
13. HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphataemic rickets. Nat Genet 1995;11:130-136.
14. 14a D'Adamio L, Shipp MA, Masteller EL, Reinherz EL: Organisation of the gene encoding common acute lymphoblastic leukaemia antigen (neutral endopeptidase 24,11): Multiple miniexons and separate 5′-untranslated regions. Proc Natl Acad Sci USA 1989;86:7103-7107.
15. 14b Rowe PSN, Oudet C, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher M-A, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanaver A, Lehrach H, Goulding J, O'Riordan JLH: Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 1997; 6:539-549.
16. Chingwen L, Hersh LB: Neprilysin: Assay methods, purification, and characterisation. Methods Enzymol 1995;248:253-263.
17. Vijayaragahavan J, Kim YA, Jackson D, Orlowsky M, Hersch LB: Use of site directed mutagenesis to identify valine 573 in the S' 1 binding site of rat neutral endopeptidase 22.11 (enkephalinase). Biochemistry 1990;29:8052-8056.
18. Leek JC, Vogler JB, Gershwin ME, Golub MS, Hurley LS, Hendrickx AG: Studies of marginal zinc deprivation in rhesus monkeys: Foetal and infant skeletal effects. Am J Clin Nutr 1984;40: 1203-1212.
19. Ship MA, Stefano GB, D'Adamio L, Switzer SN, Howard FD, Sinisterra J, Scarrer B, Reinherz EL: Down regulation of enkepahlin-mediated inflammatory responses by CD10/neutral endopeptidase 24.11. Nature 1990;347: 394-396.
20. Ship MA, Tarr Ge, Chen Cy, Switzer SN, Hersch LB, Stein H, Sunday ME, Reinherz EL: CD10/neutral endopeptidase 24.11 hydrolyses bombesin like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acd Sci USA 1991;88:10662-10666.
21. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, Yanagisawa M: ECE-1: A membrane bound metalloprotease that catalyses the proteolytic activation of Big endothelin-1. Cell 1994;78:473-485.
22. Yorimitsu K, Moroi K, Inagaki N, Saito T, Masuda Y, Masaki T, Seino S, Kimura S: Cloning and sequencing of a human endothelial converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2. Biochem Biophys Res Commun 1995;208:721-727.
23. Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, Carroll RJ, Paigen BJ, Leiter EH: Hyperinsulinaemia in obese fat/ fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995;10:135-142.
24. Strom TM, Francis F, Econs MJ, Lorenz D, Meindl A, Rowe PSN, O'Riordan JLH, Oudet C, Drezner MK, Lehrach H, Meitinger T: The mouse homolog of PEX is deleted in Gy mice. Eur J Hum Genet 1996;4(suppl 1):1.
25. 3 catabolism in X-linked hypophosphataemic rickets. Endocrinology 1994;134:1761-1767.
26. Tenenhouse HS, Jones G: Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphataemic rickets. J Clin Invest 1990;85:1450-1455.
27. 3 in murine X-linked hypophosphataemic rickets. J Clin Invest 1988;81:461-465.
28. + phosphate transporter in vitamin D resistant hypophosphataemic mice. J Biol Chem 1991;266: 13616-13620.
29. + phosphate cotransport in murine X-linked hypophosphataemic rickets: Molecular characterisation. J Clin Invest 1994;93:671-676.
30. Werner A, Moore ML, Mantei N, Biber J, Semanza G, Murer H: Cloning and expression of cDNA for Na/Pi co-transport system of kidney cortex. Proc Natl Acad Sci USA 1991;88: 9608-9612.
31. 3 and its physiological implications. Steroids 1987;49:29-53.
32. Cowgill LD, Goldfarb S, Lau K, Slatopolsky E, Agus ZS: Evidence for an intrinsic renal tubular defect in mice with genetic hypophosphataemic rickets. J Clin Invest 1979;63:1203-1210.
33. Giasson SD, Brunetti MG, Danan G, Vigneault N, Carriere S: Micropuncture study of renal phosphorus transport in hypophosphataemic vitamin D resistant rickets in mice. Pflügers Arch 1977;371:33-38.
34. Tenenhouse HS, Scriver CR, McInnes RR, Glorieux FH: Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphataemic male mouse: Evidence for a defect in the brush border membrane. Kidney Int 1978;14:236-244.
35. Tenenhouse HS, Klugerman AH, Neal JL: Effect of phosphonoformic acid dietary phosphate and the Hyp mutation on kinetically distinct phosphate transport processes in mouse kidney. Biochim Biophys Acta 1989;984:207-213.
36. Glorieux FH, Marie PJ, Pettifor J, Delvin EE: Bone response to phosphate salts, ergocalciferol and calcitriol in hypophosphataemic vitamin D resistant rickets. N Engl J Med 1980; 303:1023-1031.
37. 3 in the young X-linked hypophosphataemic male mouse. Endocrinology 1982;111:904-911.
38. Ecarot-Charrier B, Glorieux FH, Travers R, Desbarats M, Bouchard F, Hinek A: Defective bone formation by transplanted Hyp bone cells into normal mice. Endocrinology 1988;123: 768-773.
39. Ecarot B, Glorieux FH, Desbarats M, Travers R, Labelle L: Defective bone formation by Hyp mouse bone cells transplanted into normal mice: Evidence in favour of an intrinsic osteoblast defect. J Bone Miner Res 1992;7:215-220.
40. Ecarot B, Glorieux FH, Desbarats M, Travers R, Labelle L: Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J Bone Miner Res 1992;7:523-530.
41. 3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphataemic mice. J Bone Miner Res 1995; 10:424-431.
42. 3. Bone 1992;13: 209-215.
43. Rifas L, Gupta A, Hruska KA, Avioli LV: Altered osteoblast gluconeogenesis in X-linked hypophosphataemic mice is associated with a depressed intracellular pH. Calcif Tissue Int 1995;57:60-63.
44. Ecarot B, Caverzasio J, Debarats M, Bonjour J-P, Glorieux FH: Phosphate transport by osteoblasts from X-linked hypophosphataemic mice. Am J Physiol 1994;266:E33-E38.
45. Rifas L, Dawson LL, Halstead LR, Roberts M, Avioli LV: Phosphate transport in osteoblasts from normal and X-linked hypophosphataemic mice. Calcif Tissue Int 1994;54:505-510.
46. Gundberg CM, Clough ME, Carpenter TO: Development and validation of a radioimmunoassay for mouse osteocalcin: Paradoxical response in the Hyp mouse. Endocrinology 1992; 130:1909-1915.
47. Econs MJ, Drezner MK: Tumour induced osteomalacia: Unveiling a new hormone. N Engl J Med 1994;330:1679-1681.
48. Meyer RA Jr, Meyer MH: Parabiosis suggests a humoral factor is involved in X-linked hypophosphataemia in mice. J Bone Miner Res 1989;4:493-500.
49. Meyer RA Jr, Tenenhouse HS, Me yer MA, Klugerman AH: The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphataemic mice persists after parathyroidectomy. J Bone Miner Res 1989;4:523-532.
50. Meyer RA Jr, Meyer MA, Gray RW: Parabiosis of GYRO (Gy) mice: Are there two forms of X-linked hypophosphataemia? J Bone Miner Res 1993;8:135.
51. Nesbitt T, Coffman TM, Griffith R, Drezner MK: Crosstransplantation of kidneys in normal and Hyp mice. J Clin Invest 1992;89: 1453-1459.
52. Morgan JM, Hawley WL, Chenoweth AI, Retan WJ, Diethelm MD: Renal transplantation in hypophosphataemia with vitamin D resistant rickets. Arch Intern Med 1974;134:549-552.
53. Nesbitt T, Econs MJ, Byun JK, Martel J, Tenenhouse HS, Drezner MK: Phosphate transport in immortalised cell cultures from the renal proximal tubule of normal and Hyp mice: Evidence that the HYP gene locus product is an extrarenal factor. J Bone Miner Res 1995;10: 1327-1333.
54. Qiu ZQ, Tenenhouse HS, Scriver CR: Parental origin of mutant allele does not explain absence of gene dose effect in X-linked Hyp mice. Genet Res 1993;62:39-43.
55. Petersen DJ, Boniface AM, Schranck FW, Rupich RC, Whyte MP: X-linked hypophosphataemic rickets: A study with literature review of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res 1992;7:583-597.
56. Seikaly MG, Browne RH, Baum M: The effect of phosphate supplementation on linear growth in children with X-linked hypophosphatemia. Pediatrics 1994;94:478-481.
57. Thabet MA, Truchina O, Chan JC: X-linked hypophosphatemia: Molecular biology and treatment controversies. Acta Paediatr Sin 1994;35:180-187.
58. Lyon MF: X-chromosome inactivation and the location and expression of X-linked genes. Am J Hum Genet 1988;42:8-16.
59. Fisher E, Scambler P: Human haploinsufficiency: One for sorrow two for joy. Nat Genet 1995; 10:135-142.
60. Bell CL, Tenenhouse HS, Scriver CR: Primary cultures of renal epithelial cells from X-linked (Hyp) mice express defect in phosphate transport and vitamin D metabolism. Am J Hum Gent 1988;43:293-303.
61. Aschinberg LC, Solomon LM, Zeis PM, Justice P, Rosenthal IM: Vitamin D resistant rickets associated with epidermal nevus syndrome: Demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 1977;91:56-60.
62. Popovtzer MM: Tumour induced hypophosphataemic osteomalacia: Evidence for a phosphaturic cyclic AMP-independent action of tumour extract (abstract). Clin Res 1981;29:418.
63. Miyauchi A, Fukase M, Tsutsumi M, Fujita T: Haemangiopericytoma induced osteomalacia: Tumour transplantation in nude mice causes hypophosphataemia and tumour extracts inhibit renal 25-hydroxyvitamin D 1α-hydroxylase activity. J Clin Endocrinol Metab 1988;67: 46-53.
64. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmeister AR, Kumar R: Brief report: Inhibition of renal phosphate transport by a tumour product in a patient with ongogenic osteomalacia. N Engl J Med 1994;330:1645-1649.
65. Rowe PSN, Ong ACM, Cockerill FJ, Goulding JN, Hewison M: Candidate 56 and 48 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphataemic osteomalacia. Bone 1996;18:159-169.
66. Ford DM, Molitoris BA: Abnormal proximal tubule apical membrane composition in X-linked hypophosphataemic mice. Am J Physiol 1991;260:F317-F322.
67. Mingqi L, Wagner GF, Renfro JL: Stanniocalcin stimulates phosphate reabsorption by flounder remnal proximal tubule in primary culture. Am J Physiol 1994;267:R1356-R1362.
68. Wagner GF, Guiraudon CC, Milliken C, Copp DH: Immunological and biological evidence for a stanniocalcin-like hormone in human kidney. Proc Natl Acad Sci USA 1995;92:1871-1875.
69. Mallette LE: Parathyroid hormone and parathyroid hormone-related protein as polyhormones: Evolutionary aspects and non-classical actions; in Bilezikian JP (ed): The Parathyroids: Basic and Clinical Concepts. New York, Raven Press, 1994, chap 12, pp 171-185.
70. Boneh A, Mandla S, Tenenhouse HS: Phorbol myristate acetate activates protein kinase C, stimulates phosphorylation of endogenous proteins and inhibits phosphate transport in mouse renal tubules. Biochim Biophys Acta 1989;1012:308-316.
71. 3 24 hydroxylase cytochrome P450 messenger ribonucleic acid levels in primary cultures of rat renal cells. Endocrinology 1993;132:1782-1788.
72. 3-24-hydroxylase. Endocrinology 1990;127:2639-2647.
73. Tenenhouse HS, Henry HL: Protein kinase activity and protein kinase inhibitor in mouse kidney: Effect of the X-linked Hyp mutation and vitamin D status. Endocrinology 1985; 117:1719-1726.
74. Khamlichi S, Bailly P, Blanchard D, Goossens D, Cartron JP, Bertrand O: Purification and partial characterisation of the erythrocyte Kx protein deficient in McLeod patients. Eur J Biochem 1995;228:931-934.
75. Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP: Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994;77.869-880.